NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY
All drug companies offer good value right now. Prefers Bristol Myers Squibb.
TOP PICK
US is making progress on a medicare drug plan. 17 X this years earnings and 16 X next. Great pipeline. The stock has underperformed.A lot of free cash flow.
BUY
US pharmaceuticals are looking cheaper than they have in some time.
PAST TOP PICK
(Was a top pick on Sept 18/02. Up 10%.) Still likes. Thought they would have been higher. Have the most new products coming on line.
DON'T BUY
Has been stuck under a major technical resistance of $33/34. Could have a drop.
PAST TOP PICK
(Was a top pick on Apr 16/03. Not much change.) Still likes. Continuing to buy at this price.
PAST TOP PICK
(Was a top pick on Mar 31/03. Up 6.8%) Still likes. Merger with Pharmacia gives them a very powerful potent drug patent.
HOLD
Questioner: "Why is it stuck in a $30/31 range?" Response: "Likes at this price. Their drugs and pipeline are good. Has a lot of cash."
BUY
A favourite drug stock in their funds. Earnings growth should be 15% over the next several years. Dividend yield is decent. Has a very good pipeline of drugs.
TOP PICK
Just completed a good merger with Pharmacia. Good pipeline.
TOP PICK
Just got approval on new products and should move up.
DON'T BUY
More expensive in the drug sector. Merk is a better buy.
BUY
Pretty good value. The merger will allow some cost cutting. A good price.
BUY
HOLD
Well run and strong management. Has grown so big that future growth is difficult.
Showing 781 to 795 of 890 entries